Abstract
Many viruses infect hepatocytes. On the one hand an understanding of the underlying molecular mechanisms can be used to block infection by pathogenic viruses, on the other hand hepatotropic viruses can be utilized in gene therapy approaches for the directed delivery of genetic material into hepatocytes. The hepatitis C virus (HCV) follows a complex cell entry route utilizing at least four essential cell surface receptors on hepatocytes. Inhibitors of HCV cell entry are in early clinical development and could useful for the prevention of HCV reinfection of the graft after liver transplantation. Although much less is known about the cell entry of hepatitis B virus and hepatitis D virus (HBV; HDV) it can be blocked efficiently by active or passive immunization. Moreover, a highly specific lipopeptide entry inhibitor based on a fragment of the HBV envelope is in clinical development. Finally, approaches are being developed to use hepatotropic viruses to correct genetic defects in hepatocytes. Especially adeno-associated virus based vector systems have recently shown promising results in proof-of-concept studies.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.